SCHEMBL24933227

SCHEMBL24933227

NC(=O)c1cc(-c2ccc(OCc3cnc(CC4CCCC4)nc3)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 6/20 0.37
S1PR1 P21453 1/20 0.36
PARP10 Q53GL7 5/20 0.35
GRM2 Q14416 1/20 0.34
PARP15 Q460N3 4/20 0.34
MAOB P27338 2/20 0.33
CAMKK2 Q96RR4 1/20 0.33
CHEK2 O96017 1/20 0.33
HSD17B1 P14061 2/20 0.33
HSD17B2 P37059 2/20 0.33
HDAC3 O15379 1/20 0.33
PARP1 P09874 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933810 0.87 FFAR4 (0.40) GRM2MAOBCHEK2HSD17B1HSD17B2
SCHEMBL24933795 0.86 MKNK1 (0.35) MAOBCHEK2HSD17B1HSD17B2HDAC3
SCHEMBL24933812 0.86 SYK (0.39)
SCHEMBL24933385 0.85 PARP1 (0.39) PARP10MAOBCHEK2HSD17B1HSD17B2
SCHEMBL24932994 0.84 MAOB (0.35) S1PR1PARP10MAOBCHEK2HSD17B1
SCHEMBL24932967 0.84 FFAR1 (0.36) MAOBHSD17B1HSD17B2
SCHEMBL24932987 0.84 SYK (0.40) MAOBHSD17B1HSD17B2PARP1
SCHEMBL30240713 0.83 CCR6 (0.40) MAOB
SCHEMBL24933633 0.83 PARP10 (0.53) PARP10PARP15MAOBCHEK2
SCHEMBL24933463 0.83 HSD17B1 (0.41) PARP10MAOBCHEK2HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed